

**For filings with the FCA include the annex**  
**For filings with issuer exclude the annex**

**TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES<sup>i</sup>**

<b>1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii</b>	INTEGRATED DIAGNOSTICS HOLDINGS PLC
<b>2 Reason for the notification</b> (please tick the appropriate box or boxes):	
An acquisition or disposal of voting rights	X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached	
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments	
An event changing the breakdown of voting rights	
Other (please specify):	
<b>3. Full name of person(s) subject to the notification obligation: iii</b>	T. Rowe Price Associates, Inc.

<b>4. Full name of shareholder(s)</b> (if different from 3.): <sup>iv</sup>	JP Morgan Chase Bank of New York Mellon Bank, N.A. Northern Trust Co.
<b>5. Date of the transaction and date on which the threshold is crossed or reached:</b> <sup>v</sup>	08 March 2017
<b>6. Date on which issuer notified:</b>	10 March 2017
<b>7. Threshold(s) that is/are crossed or reached:</b> <sup>vi, vii</sup>	5%

<b>8. Notified details:</b>						
<b>A: Voting rights attached to shares</b> <sup>viii, ix</sup>						
Class/type of shares  if possible using the ISIN CODE	Situation previous to the triggering transaction	Resulting situation after the triggering transaction				
		Number of Shares	Number of Voting Rights	Number of voting rights		% of voting rights <sup>x</sup>
				Direct <sup>xi</sup>	Indirect <sup>xii</sup>	
JE00BV9H9G76	7,474,850	7,474,850	7,570,134	7,570,134		5.04%

<b>B: Qualifying Financial Instruments</b>				
Resulting situation after the triggering transaction				
Type of financial instrument	Expiration date <sup>xiii</sup>	Exercise/Conversion Period <sup>xiv</sup>	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights

<b>C: Financial Instruments with similar economic effect to Qualifying Financial Instruments</b> xv, xvi					
Resulting situation after the triggering transaction					
Type of financial instrument	Exercise price	Expiration date	Conversion period	Number of voting rights instrument defers to	% of voting rights xix, xx
					Nominal
					Delta

<b>Total (A+B+C)</b>	
Number of voting rights	Percentage of voting rights
7,570,134	5.04%

<b>9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:</b> xxi
<p>T. Rowe Price Associates, Inc. (TRPA) serves as investment adviser, with dispositive and voting authority, to various institutional clients that own shares of Integrated Diagnostics Holding Plc., including the T. Rowe Price International Discovery Fund, which owns 5,391,836 shares. Such shares are registered in the following name(s):</p> <p>Bank of New York Mellon Bank, N.A. - 337,429</p> <p>JP Morgan Chase - 7,172,393</p> <p>Northern Trust Co. - 60,312</p>

<b>Proxy Voting:</b>	
<b>10. Name of the proxy holder:</b>	
<b>11. Number of voting rights proxy holder will cease to hold:</b>	

<b>12. Date on which proxy holder will cease to hold voting rights:</b>	
---	--

<b>13. Additional information:</b>	
<b>14. Contact name:</b>	Gary Greb, Vice President T. Rowe Price Associates, Inc.
<b>15. Contact telephone number:</b>	001 410 345 2527

This information is provided by RNS  
The company news service from the London Stock Exchange

END

HOLURVSRBSAOAAR